Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Inspire Medical Systems, Inc. (INSP)

Core Viewpoint - A securities class action lawsuit has been filed against Inspire Medical Systems, Inc. for allegedly misleading investors regarding the launch and demand for its Inspire V device, leading to significant stock price declines and loss of market capitalization [1][2][3]. Group 1: Allegations and Misrepresentation - The Complaint claims that Defendants made false statements and failed to disclose critical information about the market demand for Inspire V and the necessary steps for its successful launch [2]. - It is alleged that Defendants misled investors into believing that demand for Inspire V was strong, while in reality, the launch faced significant delays due to incomplete training and onboarding at treatment centers [2]. - The Complaint states that the rollout of Inspire V was hindered by poor demand and excess inventory, resulting in a drastic reduction of the Company's 2025 earnings guidance by over 80% [2]. Group 2: Stock Price Impact - Following the revelation of these issues on August 4, 2025, Inspire Medical's stock price plummeted by more than 32%, from $129.95 to $87.91 per share, erasing $1.2 billion in market capitalization in one day [3]. - The stock price had previously reached a high of $216.71 per share on September 23, 2024, indicating a nearly 60% decline, equating to a loss of billions in market capitalization [3]. Group 3: Class Action Participation - Investors who purchased Inspire Medical common stock during the Class Period may seek to be appointed as lead plaintiffs in the class action lawsuit, as per the provisions of the Private Securities Litigation Reform Act of 1995 [4]. - Interested investors are encouraged to contact the law firm Gainey McKenna & Egleston before the lead plaintiff motion deadline on January 5, 2026 [5].